China’s First IOL Agreements Lapsed at the End of May. The Renewal Playbook Now Exists, Just Not for Lenses.
China's first-wave IOL agreements lapsed end-May 2026 with no renewal scheme, even as the coronary stent renewal set out the device playbook. OphthalLogix reads a mild reduction ahead, not a steep one
China’s first provincial intraocular-lens procurement agreements lapsed at the end of May 2026. As of 1 June, no second-round scheme, transitional notice, or national guidance has been published for them. In the same fortnight, China renewed coronary stent procurement for a second cycle, the device renewal playbook is now in plain view, and none of it has been applied to lenses.
The expiry is staggered, not national
The fourth national volume-based procurement round for intraocular lenses ran a two-year cycle, executed province by province. The first wave, Guangxi, Guangdong and Shenzhen, live from 30 May 2024, reached its two-year mark around 30 May 2026. Beijing follows on 28 June; Hunan on 30 June. The exposure is sequential, and the first-wave provinces carry it first.
What is missing is the administrative sequence that normally precedes expiry. A provincial medical security bureau confirms volume commitments, price schedules and signatories before the prior agreement ends. For the first-wave provinces, none of that has appeared. The most recent national platform notice, dated 30 April 2026, was a routine product-maintenance note, no renewal content, thirty days before the first agreements lapsed. The silence is the signal.
The renewal playbook now exists
The contrast is sharp because the renewal mechanism is no longer hypothetical. On 20 May 2026, the second-round renewal of coronary stent procurement opened in Tianjin (采购文件编号 GH-HD2026-1). Fifteen manufacturers tendered thirty products; every bidder won, and twenty-seven products were tentatively selected. The design is instructive: prices set by inquiry rather than competitive undercutting, procurement volume tied to price tier, and an explicit principle of stabilising clinical supply, protecting quality and curbing involution. Newly approved products may apply for supplementary selection mid-cycle. This is the device renewal playbook, demonstrated on the first device category China ever procured at a national scale.
A provincial template exists as well. The Inner Mongolia transitional procurement notice No. 255 (内药采中心字 [2025] 255号), issued on 17 December 2025, kept expired alliance device agreements in place at their original prices and extended the transitional category to 30 June 2026 on a single, light-touch notice. Bridging an expiry is administratively trivial. It has not been issued for intraocular lenses.
The gap
This is the policy-execution gap in its clearest form, not the absence of a precedent, but a complete one, demonstrated on coronary stents and available as a provincial transitional tool, that has not been extended to intraocular lenses. The coronary rules will not transfer line by line; a stent and a trifocal lens are different products, but the regulator now holds a worked, recent answer to the question the IOL provinces are asking. The information asymmetry is the cost. The first-wave provinces had seventeen days to improvise what Inner Mongolia had prepared five and a half months in advance.
What the books already show
The corporate record already prices in a move. In February 2026, Haohai Biotech (688366) booked a goodwill impairment of RMB 141 million against its IOL distribution subsidiary, citing an expected second-round price cut in the first half of 2026. The accounting was completed in February; the first half ends on 30 June. A price event recognised in the books must now either materialise or force a revision.
How far prices move
On magnitude, OphthalLogix’s reading is that the renewal discount is more likely to be mild than steep, a deeper cut is the main downside risk, not the central case. The first round already compressed IOL prices by around 60 per cent. The structural floor has been tested, and the regulator’s stated direction against involution works against another deep cut. A category-specific mechanism, with room for a separate premium track, fits the policy direction better. Independent market analysis points the same way.
What hospitals do in the interval
The more useful question is what hospitals do in the interval. The likeliest response, in our assessment, is continuity: most will keep ordering selected lenses at the original prices while managing volume down, rather than freeze procurement or switch to higher non-selected listings. Cataract surgery is elective. Admissions teams confirm lens model and price before a patient enters the ward, not in theatre, so the friction point is the scheduling decision, not the operating table. The rational response to a short, uncertain window is to control incoming volume, not to stop, and not to expose patients to a sudden out-of-pocket increase. Hospitals take their lead from the policy file; with a new framework expected within weeks, few will step outside it and risk unwinding the position once it arrives.
Key Implications
For teams managing China device portfolios, this is not yet a pricing decision; it is a forecasting and reporting gap. The renewal magnitude cannot be locked, but the probability distribution has narrowed: a mild reduction, a category-specific design, and a premium segment defended on clinical grounds. Distributors cannot default to the old price as a commercial choice; provincial platform configuration governs what can be ordered, so operational risk concentrates wherever a platform closes the prior-agreement entry before a transitional notice arrives. The audit overlay tightens the timing; the 2026 national medical insurance fund inspection programme, set out in the supervision notice of 2 February 2026 and formally launched on 14 May 2026, with ophthalmology among its priority areas, so the compliance window and the procurement window now coincide. Watch for a national or first-wave transitional notice through early to mid-June; its absence past Beijing’s 28 June expiry would carry the vacuum into a second wave.
— The OphthalLogix Intelligence Team
This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content. intelligence@ophthallogix.com · www.ophthallogix.com